Hasil Pencarian - Sine R Hadrup

  • Menampilkan 1 - 4 hasil dari 4
Perbaiki Hasil
  1. 1
    Preclinical evaluation of NF-κB-triggered dendritic cells expressing the viral oncogenic driver of Merkel cell carcinoma for therapeutic vaccination

    Preclinical evaluation of NF-κB-triggered dendritic cells expressing the viral oncogenic driver of Merkel cell carcinoma for therapeutic vaccination oleh Kerstin F. Gerer, Michael Erdmann, Sine R. Hadrup, Rikke Lyngaa, Lena-Marie Martin, Reinhard E. Voll, Beatrice Schuler-Thurner, Gerold Schuler, Niels Schaft, Stefanie Hoyer, Jan Dörrie

    Diterbitkan 2017-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    High-throughput identification of potential minor histocompatibility antigens by MHC tetramer-based screening: feasibility and limitations.

    High-throughput identification of potential minor histocompatibility antigens by MHC tetramer-based screening: feasibility and limitations. oleh Pleun Hombrink, Sine R Hadrup, Arne Bakker, Michel G D Kester, J H Frederik Falkenburg, Peter A von dem Borne, Ton N M Schumacher, Mirjam H M Heemskerk

    Diterbitkan 2011-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    NetTCR-2.0 enables accurate prediction of TCR-peptide binding by using paired TCRα and β sequence data

    NetTCR-2.0 enables accurate prediction of TCR-peptide binding by using paired TCRα and β sequence data oleh Alessandro Montemurro, Viktoria Schuster, Helle Rus Povlsen, Amalie Kai Bentzen, Vanessa Jurtz, William D. Chronister, Austin Crinklaw, Sine R. Hadrup, Ole Winther, Bjoern Peters, Leon Eyrich Jessen, Morten Nielsen

    Diterbitkan 2021-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial

    Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised contr... oleh Relinde I. Y. Lieverse, Evert J. Van Limbergen, Cary J. G. Oberije, Esther G. C. Troost, Sine R. Hadrup, Anne-Marie C. Dingemans, Lizza E. L. Hendriks, Franziska Eckert, Crispin Hiley, Christophe Dooms, Yolande Lievens, Monique C. de Jong, Johan Bussink, Xavier Geets, Vincenzo Valentini, Giuliano Elia, Dario Neri, Charlotte Billiet, Amir Abdollahi, David Pasquier, Pierre Boisselier, Ala Yaromina, Dirk De Ruysscher, Ludwig J. Dubois, Philippe Lambin

    Diterbitkan 2020-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: